In addition, colonosphere formation assay and ELDA analysis reveal that tamoxifen could inhibit the capacity of colonosphere formation and decrease the sphere formation rates in the presence of LNX1, which demonstrated it as a potential target for colorectal carcinoma therapy against CSCs (Fig 4C and 4D). This evidence concerns the gene LNX1 and colorectal carcinoma.